Newborn screening for severe combined immunodeficiency and inborn errors of immunity

Curr Opin Pediatr. 2023 Dec 1;35(6):692-702. doi: 10.1097/MOP.0000000000001291. Epub 2023 Sep 14.

Abstract

Purpose of review: Severe combined immune deficiency (SCID) is the most devastating genetic disease of the immune system with an unfavorable outcome unless diagnosed early in life. Newborn screening (NBS) programs play a crucial role in facilitating early diagnoses and timely interventions for affected infants.

Recent findings: SCID marked the pioneering inborn error of immunity (IEI) to undergo NBS, a milestone achieved 15 years ago through the enumeration of T-cell receptor excision circles (TRECs) extracted from Guthrie cards. This breakthrough has revolutionized our approach to SCID, enabling not only presymptomatic identification and prompt treatments (including hematopoietic stem cell transplantation), but also enhancing our comprehension of the global epidemiology of SCID.

Summary: NBS is continuing to evolve with the advent of novel diagnostic technologies and treatments. Following the successful implementation of SCID-NBS programs, a call for the early identification of additional IEIs is the next step, encompassing a broader spectrum of IEIs, facilitating early diagnoses, and preventing morbidity and mortality.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • DNA
  • Early Diagnosis
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Infant, Newborn
  • Neonatal Screening
  • Receptors, Antigen, T-Cell / genetics
  • Severe Combined Immunodeficiency* / diagnosis
  • Severe Combined Immunodeficiency* / genetics
  • Severe Combined Immunodeficiency* / therapy

Substances

  • DNA
  • Receptors, Antigen, T-Cell